GSK vs. TEM: GSK vs. Tempus AI Stock Comparison

Company Profile

GSK (GSK) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GSK is classified in Pharmaceuticals while TEM is classified in Life Sciences Tools & Services.

GSK (GSK) carries decades of public-market history since March 28, 1980, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the GSK side.

Tempus AI (TEM) trades as ordinary local shares, while GSK (GSK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Tempus AI (TEM) has a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, while GSK (GSK) is defensive at 0.31 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Tempus AI (TEM) reports a negative ROE of -37.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile GSK (GSK) reports 28.27%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile GSK (GSK) reports 12.97%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile GSK (GSK) reports 32.14%, ranking against industry peers normally.

Profitability Metrics

Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while GSK (GSK) at 4.11% is closer to the peer norm — faster top-line expansion for TEM.

Only one side can be read here: GSK (GSK) reports EPS growth of 123.15%, ranked against its industry; Tempus AI (TEM) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Tempus AI (TEM) at 2.61 keeps current ratio within its industry’s typical mid-range, while GSK (GSK) at 0.86 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GSK.

Both balance sheets lean debt-heavy versus peers, but TEM is more stretched: GSK (GSK) at 1.30 sits in the higher-leverage quartile and Tempus AI (TEM) at 2.86 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Tempus AI (TEM) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a yield of 1.57%, ranking against industry peers normally.

Tempus AI (TEM) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a payout of 63.33%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: GSK (GSK) trades at 17.54 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.

GSK (GSK) at 3.01 sits in the cheaper P/S ratio quartile while Tempus AI (TEM) at 9.19 prices around its industry’s middle — GSK costs less per dollar of sales, though read it alongside growth and margins.

GSK (GSK) at 4.02 sits near its industry’s typical P/B ratio, while Tempus AI (TEM) at 27.66 prices above its benchmark range — TEM looks rich relative to book.

Valuation Metrics